Page last updated: 2024-11-05

thalidomide and Adenoma, Prolactin-Secreting, Pituitary

thalidomide has been researched along with Adenoma, Prolactin-Secreting, Pituitary in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stepień, H1
Lawnicka, H1
Mucha, S1
Wagrowska-Danilewicz, M1
Stepień, B1
Siejka, A1
Komorowski, J1

Other Studies

1 other study available for thalidomide and Adenoma, Prolactin-Secreting, Pituitary

ArticleYear
Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
    Life sciences, 2006, Sep-27, Volume: 79, Issue:18

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Nucleus; Cell Proliferation; Diethylstilbestrol; E

2006